Moleculin Biotech, Inc. (NASDAQ:MBRX) Sees Significant Increase in Short Interest

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a large increase in short interest during the month of July. As of July 31st, there was short interest totaling 1,577,365 shares, an increase of 49.6% from the July 15th total of 1,054,620 shares. Approximately 22.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,913,836 shares, the days-to-cover ratio is currently 0.8 days.

Moleculin Biotech Stock Performance

Shares of NASDAQ:MBRX traded up $0.00 during trading on Tuesday, hitting $0.61. The company’s stock had a trading volume of 232,417 shares, compared to its average volume of 573,893. The company has a market capitalization of $4.33 million, a PE ratio of -0.03 and a beta of 1.84. Moleculin Biotech has a fifty-two week low of $0.16 and a fifty-two week high of $15.75. The stock’s 50-day moving average price is $1.99 and its two-hundred day moving average price is $2.45.

Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.40) earnings per share for the quarter, topping the consensus estimate of ($1.55) by $0.15. On average, equities analysts predict that Moleculin Biotech will post -3.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Moleculin Biotech

A hedge fund recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC acquired a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech at the end of the most recent quarter. 15.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on MBRX. Wall Street Zen raised Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Moleculin Biotech presently has a consensus rating of “Hold” and a consensus price target of $22.00.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.